Literature DB >> 29602830

3β-Methyl-Neurosteroid Analogs Are Preferential Positive Allosteric Modulators and Direct Activators of Extrasynaptic δ-Subunit γ-Aminobutyric Acid Type A Receptors in the Hippocampus Dentate Gyrus Subfield.

Shu-Hui Chuang1, Doodipala Samba Reddy2.   

Abstract

Neurosteroids are powerful modulators of γ-aminobutyric acid (GABA)-A receptors. Ganaxolone (3α-hydroxy-3β-methyl-5α-pregnan-20-one, GX) and synthetic analogs of the neurosteroid allopregnanolone (AP) are designed to treat epilepsy and related conditions. However, their precise mechanism of action in native neurons remains unclear. Here, we sought to determine the mode of action of GX and its analogs at GABA-A receptors in native hippocampal neurons by analyzing extrasynaptic receptor-mediated tonic currents and synaptic receptor-mediated phasic currents. Concentration-response profiles of GX were determined in two cell types: δ-containing dentate gyrus granule cells (DGGCs) and γ2-containing CA1 pyramidal cells (CA1PCs). GX produced significantly greater potentiation of the GABA-A receptor-activated chloride currents in DGGCs (500%) than CA1PCs (200%). In the absence of GABA, GX evoked 2-fold greater inward currents in DGGCs than CA1PCs, which were 2-fold greater than AP within DGGCs. In hippocampus slices, GX potentiated and directly activated tonic currents in DGGCs. These responses were significantly diminished in DGGCs from δ-subunit knockout (δKO) mice, confirming GX's selectivity for δGABA-A receptors. Like AP, GX potentiation of tonic currents was prevented by protein kinase C inhibition. Furthermore, GX's protection against hippocampus-kindled seizures was significantly diminished in δKO mice. GX analogs exhibited greater potency and efficacy than GX on δGABA-A receptor-mediated tonic inhibition. In summary, these results provide strong evidence that GX and its analogs are preferential allosteric modulators and direct activators of extrasynaptic δGABA-A receptors regulating network inhibition and seizures in the dentate gyrus. Therefore, these findings provide a mechanistic rationale for the clinical use of synthetic neurosteroids in epilepsy and seizure disorders.
Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29602830      PMCID: PMC5941194          DOI: 10.1124/jpet.117.246660

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  83 in total

Review 1.  Altered expression of δGABAA receptors in health and disease.

Authors:  Paul D Whissell; Irene Lecker; Dian-Shi Wang; Jieying Yu; Beverley A Orser
Journal:  Neuropharmacology       Date:  2014-08-13       Impact factor: 5.250

2.  Perimenstrual-like hormonal regulation of extrasynaptic δ-containing GABAA receptors mediating tonic inhibition and neurosteroid sensitivity.

Authors:  Chase Matthew Carver; Xin Wu; Omkaram Gangisetty; Doodipala Samba Reddy
Journal:  J Neurosci       Date:  2014-10-22       Impact factor: 6.167

3.  Enantioselectivity of pregnanolone-induced gamma-aminobutyric acid(A) receptor modulation and anesthesia.

Authors:  D F Covey; D Nathan; M Kalkbrenner; K R Nilsson; Y Hu; C F Zorumski; A S Evers
Journal:  J Pharmacol Exp Ther       Date:  2000-06       Impact factor: 4.030

4.  Catamenial-like seizure exacerbation in mice with targeted ablation of extrasynaptic δGABA-a receptors in the brain.

Authors:  Bryan L Clossen; Doodipala Samba Reddy
Journal:  J Neurosci Res       Date:  2017-02-25       Impact factor: 4.164

5.  Anticonvulsant activity of neurosteroids: correlation with gamma-aminobutyric acid-evoked chloride current potentiation.

Authors:  T G Kokate; B E Svensson; M A Rogawski
Journal:  J Pharmacol Exp Ther       Date:  1994-09       Impact factor: 4.030

6.  Protective efficacy of neuroactive steroids against cocaine kindled-seizures in mice.

Authors:  Rafal M Kaminski; Maciej Gasior; Richard B Carter; Jeffrey M Witkin
Journal:  Eur J Pharmacol       Date:  2003-08-08       Impact factor: 4.432

7.  GABA(A) receptor delta subunit deletion prevents neurosteroid modulation of inhibitory synaptic currents in cerebellar neurons.

Authors:  Stefano Vicini; Gabriele Losi; Gregg E Homanics
Journal:  Neuropharmacology       Date:  2002-09       Impact factor: 5.250

8.  The influence of neuroactive steroid lipophilicity on GABAA receptor modulation: evidence for a low-affinity interaction.

Authors:  Mariangela Chisari; Lawrence N Eisenman; Kathiresan Krishnan; Achintya K Bandyopadhyaya; Cunde Wang; Amanda Taylor; Ann Benz; Douglas F Covey; Charles F Zorumski; Steven Mennerick
Journal:  J Neurophysiol       Date:  2009-06-24       Impact factor: 2.714

9.  Neurosteroids promote phosphorylation and membrane insertion of extrasynaptic GABAA receptors.

Authors:  Armen M Abramian; Eydith Comenencia-Ortiz; Amit Modgil; Thuy N Vien; Yasuko Nakamura; Yvonne E Moore; Jamie L Maguire; Miho Terunuma; Paul A Davies; Stephen J Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

10.  Modulation of neurosteroid potentiation by protein kinases at synaptic- and extrasynaptic-type GABAA receptors.

Authors:  Joanna M Adams; Philip Thomas; Trevor G Smart
Journal:  Neuropharmacology       Date:  2014-09-30       Impact factor: 5.250

View more
  12 in total

Review 1.  Neuroendocrine aspects of improving sleep in epilepsy.

Authors:  Doodipala Samba Reddy; Shu-Hui Chuang; Dayton Hunn; Amy Z Crepeau; Rama Maganti
Journal:  Epilepsy Res       Date:  2018-08-31       Impact factor: 3.045

2.  Extrasynaptic γ-aminobutyric acid type A receptor-mediated sex differences in the antiseizure activity of neurosteroids in status epilepticus and complex partial seizures.

Authors:  Doodipala Samba Reddy; Chase Matthew Carver; Bryan Clossen; Xin Wu
Journal:  Epilepsia       Date:  2019-03-20       Impact factor: 5.864

3.  Isobolographic Analysis of Antiseizure Activity of the GABA Type A Receptor-Modulating Synthetic Neurosteroids Brexanolone and Ganaxolone with Tiagabine and Midazolam.

Authors:  Shu-Hui Chuang; Doodipala Samba Reddy
Journal:  J Pharmacol Exp Ther       Date:  2019-12-16       Impact factor: 4.030

4.  Zinc reduces antiseizure activity of neurosteroids by selective blockade of extrasynaptic GABA-A receptor-mediated tonic inhibition in the hippocampus.

Authors:  Shu-Hui Chuang; Doodipala Samba Reddy
Journal:  Neuropharmacology       Date:  2018-11-22       Impact factor: 5.250

Review 5.  Post-Traumatic Epilepsy and Comorbidities: Advanced Models, Molecular Mechanisms, Biomarkers, and Novel Therapeutic Interventions.

Authors:  Victoria M Golub; Doodipala Samba Reddy
Journal:  Pharmacol Rev       Date:  2022-04       Impact factor: 25.468

Review 6.  Neurosteroid replacement therapy for catamenial epilepsy, postpartum depression and neuroendocrine disorders in women.

Authors:  Doodipala Samba Reddy
Journal:  J Neuroendocrinol       Date:  2021-09-10       Impact factor: 3.870

7.  Comparative profile of refractory status epilepticus models following exposure of cholinergic agents pilocarpine, DFP, and soman.

Authors:  Doodipala Samba Reddy; Marcus Zaayman; Ramkumar Kuruba; Xin Wu
Journal:  Neuropharmacology       Date:  2021-04-18       Impact factor: 5.273

8.  Serum levels of allopregnanolone, progesterone and testosterone in menstrually-related and postmenopausal migraine: A cross-sectional study.

Authors:  Cecilia Rustichelli; Elisa Bellei; Stefania Bergamini; Emanuela Monari; Carlo Baraldi; Flavia Lo Castro; Aldo Tomasi; Anna Ferrari
Journal:  Cephalalgia       Date:  2020-06-26       Impact factor: 6.292

Review 9.  Allopregnanolone: An overview on its synthesis and effects.

Authors:  Silvia Diviccaro; Lucia Cioffi; Eva Falvo; Silvia Giatti; Roberto Cosimo Melcangi
Journal:  J Neuroendocrinol       Date:  2021-06-29       Impact factor: 3.870

Review 10.  Anti-apoptotic Actions of Allopregnanolone and Ganaxolone Mediated Through Membrane Progesterone Receptors (PAQRs) in Neuronal Cells.

Authors:  Peter Thomas; Yefei Pang
Journal:  Front Endocrinol (Lausanne)       Date:  2020-06-24       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.